Analysts Blame Affy's 'Disappointing' Q2 Revenues on Sequencing Adoption, Loss of Market Share | GenomeWeb

By Justin Petrone

Affymetrix last week said that it expects to report that its second-quarter revenues declined between 9 percent and 11 percent year over year.

And while Affy officials attributed the decline on weakness in sales to academic customers, especially in North America, several industry analysts this week linked it to increased adoption of next-generation sequencing and to competition in the array market from its main rival, Illumina.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.